Syndax (SNDX) to Initiate Phase 1b Trial of Revumenib in Combination for First-Line AML Patients with NPM1 and KMT2A Mutations
This Phase 1b trial (NCT05886049), led by the National Cancer Institute (NCI), evaluates revumenib (SNDX-5613), a Menin-KMT2A inhibitor, in combination with daunorubicin and cytarabine, the standard induction chemotherapy. Revumenib, already approved for relapsed/refractory (R/R) settings, aims to expand its use to the first-line treatment of newly diagnosed patients. This represents a significant milestone, as combining a potent targeted therapy early in the treatment course seeks to prevent early relapse and maximize cure rates. The strategy aims to overcome the limitations of the existing '7+3' standard regimen and potentially redefine the initial treatment paradigm.
The study focuses on patients with acute myeloid leukemia (AML) who have NPM1 mutations, KMT2A rearrangements, and/or NUP98 mutations, all of which are associated with poor outcomes and high relapse rates with conventional chemotherapy alone, highlighting the need for personalized treatment approaches. Revumenib is expected to directly block the survival signals in these mutated tumor cells, thereby enhancing their sensitivity to chemotherapy. The trial reflects the core principles of precision medicine by selecting patients based on specific biomarkers, aiming to improve clinical success and minimize unnecessary side effects.
Revumenib selectively inhibits the interaction of the menin-KMT2A protein complex, which promotes the transcription of leukemia-causing genes. In contrast, the standard chemotherapeutic agents, daunorubicin and cytarabine, physically inhibit DNA replication and cell division, directly inducing the death of rapidly dividing cancer cells. This combination strategy, targeting different pathways simultaneously, is highly effective in preventing the development of drug resistance through alternative mechanisms. The synergistic effect of the two mechanisms is expected to significantly increase tumor reduction and improve complete remission rates compared to single-agent use.
The acute myeloid leukemia (AML) treatment market is currently valued at approximately $4.2 billion (USD) and is projected to exceed $10 billion by the mid-2030s, making it a high-growth market. Syndax Pharmaceuticals' revumenib has already secured FDA approval for KMT2A-positive leukemia in 2024 and NPM1-mutated AML in 2025, establishing it as a market leader. However, with competitors like Kura Oncology's ziftomenib rapidly catching up, a swift entry into the first-line treatment market is crucial for maintaining its leading position. This NCI-led combination trial is expected to further solidify revumenib's market dominance by proactively securing robust clinical data.
This Phase 1b trial of revumenib represents a strategic move for Syndax (SNDX) to expand beyond its approved indications in relapsed/refractory settings and position revumenib as a first-line standard of care in the approximately $4.2 billion acute myeloid leukemia (AML) market. Having sequentially obtained FDA approvals for KMT2A-positive leukemia in November 2024 and NPM1-mutated AML in October 2025, Syndax is now at a critical juncture to outpace its competitor, Kura Oncology (KURA), and solidify its market leadership. For researchers and industry professionals, the trial offers the opportunity to evaluate the academic value and safety of combining targeted therapies with the established '7+3' chemotherapy regimen early in treatment, aiming to suppress the development of resistance and significantly improve complete remission rates. While the immediate focus is on establishing clinical safety and determining the optimal dosage, the long-term goal is to achieve inclusion in first-line treatment guidelines (NCCN Guideline), thereby expanding the target patient population and driving substantial revenue growth for the product.
Source: ClinicalTrials.gov (api_ct)